FDA approves plasmid DNA-based immunotherapy for rare viral disease

The FDA has approved a plasmid DNA-based immunotherapy for a rare viral disease, marking a significant regulatory milestone in gene-based treatments for rare conditions.

This Wire brief sits within Fusion42's coverage of Biotech.